The article identifies several novel hepatitis C virus (HCV) therapies. Topics discussed include the role of HCV genotype in determining the choice and length of treatment and cure rates for genotypes 1 and 3 patients. The effectiveness of the protease inhibitors boceprevir and telaprevir and the opportunity for patients to receive an all-oral regime made possible by anti-viral agents sofosbuvir, ledipasvir, and daclatasvir are also mentioned.